title: Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
abstract: Even in the tyrosine kinase inhibitors era, the prognosis of patients with chronic myeloid leukaemia in myeloid blast crisis remains dismal with few patients surviving longer than 6 months. Here we report the cases of 5 patients treated with the combination of 5-azacytidine and tyrosine kinase inhibitors for myeloid blast crisis CML. All patients achieved a complete haematological response including two with a complete cytogenetic and major molecular response. Two patients underwent an allogeneic stem cell transplantation. One died from relapse 34 months from diagnosis. The second is alive and free from disease at 11 months from diagnosis. The other 3 patients are still in complete haematological response after 15, 24 and 33 months of follow-up. These results suggest that the combination has a significant activity in myeloid blast crisis and may increase survival.
authors: Service d'Hématologie, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France.
authors: David
authors: D
authors: Ghez
authors: Jean-Baptiste
authors: JB
authors: Micol
authors: Florence
authors: F
authors: Pasquier
authors: Nathalie
authors: N
authors: Auger
authors: Véronique
authors: V
authors: Saada
authors: Marc
authors: M
authors: Spentchian
authors: Jean-Christophe
authors: JC
authors: Ianotto
authors: Jean-Henri
authors: JH
authors: Bourhis
authors: Anelyse
authors: A
authors: Bennaceur-Griscelli
authors: Christine
authors: C
authors: Terré
authors: Sylvie
authors: S
authors: Castaigne
authors: Sophie
authors: S
authors: Rigaudeau
authors: Philippe
authors: P
authors: Rousselot
authors: Stéphane
authors: S
authors: de Botton
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage*; D001752:Blast Crisis / Q000188:drug therapy*; D000069439:Dasatinib; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage; D013844:Thiazoles / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D001374:Azacitidine; D000069439:Dasatinib
keywords: Blast phase; Chronic myelogenous leukaemia; Tyrosine kinase inhibitors